Titan Medical Inc.
TMDIF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 12.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 82.1% | 92.7% |
| R&D Expenses | $0 | -$0 | -$0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | -$0 | -$0 | -$0 | -$0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -4.7% | -74% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | -666.5% | 15.3% |
| EPS | -0.009 | -0.007 | -0.029 | 0.001 |
| % Growth | -32.9% | 76% | -4,966.7% | – |
| EPS Diluted | -0.009 | -0.007 | -0.029 | 0.001 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | -618.8% | 31.6% |